The ADAURA trial
The plenary session at ASCO saw Prof Roy S. Herbst of the Yale Cancer Center present the overall survival analysis from the ADAURA trial on adjuvant osimertinib for patients with resected EGFR-mutated stage IB-IIIA non-small cell lung cancer. Dr. Mariana Brandao of Hôpital de Bruxelles-Institut Jules Bordet joined him in discussing these thrilling results.
With the educational support of:
